Expression and induction of CYP1A/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: A 10-year follow-up

Xenobiotica

Volumn 30, Issue 6, 2000, Pages 589-607

  Meunier, V ^a   Bourrie M ^a   Julian, B ^a   Marti, E ^a   Guillou, F ^a   Berger, Y ^a   Fabre, G ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA NAPHTHOFLAVONE; COUMARIN; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; ETHOXYRESORUFIN DEETHYLASE; NIFEDIPINE; PHENACETIN O DEETHYLASE; PHENOBARBITAL; RIFAMPICIN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; ISOENZYME; PHENACETIN;

ADULT; AGED; ARTICLE; CANCER; CELL CULTURE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; BIOSYNTHESIS; BIOTRANSFORMATION; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; KINETICS; LIVER; LIVER MICROSOME; METABOLISM; MIDDLE AGED; TIME; WESTERN BLOTTING;

ADULT; AGED; BETA-NAPHTHOFLAVONE; BIOTRANSFORMATION; BLOTTING, WESTERN; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; ISOENZYMES; KINETICS; LIVER; MALE; MICROSOMES, LIVER; MIDDLE AGED; PHENACETIN; PHENOBARBITAL; TIME FACTORS;

EID: 0033624124     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982500406426     Document Type: Article

References (41)

1. BRIQUETTE, D. J., MACKENZIE, P. I., VERONEZE, M. E. and MINERS, J. O., 1993, In vitro approaches can predict human drug metabolism. Trends in Pharmacological Sciences, 14, 292-294.
2. BOURRIÉ, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321-332.
3. BURKE, M. D., THOMPSON, S., ELCOMBE, C. R., HALPERT, J., HAAPARANTA, T. and MAYER, R. T., 1985, Ethoxy-, pentoxy-, and benzoyloxy-phenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochemical Pharmacology, 34, 3337-3345.
4. BUTLER, M. A., IWASAKI, M., GUENGERICH, F. P. and KADLUBAR F. F., 1989, Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences, USA, 86, 7696-7700.
5. COMBALBERT, J., FABRE, I., FABRE, G., DALET, C., DERANCOURT, J., CANO, J. P. and MAUREL, P., 1989, Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin-inducible human liver cytochrome (cyclosporin A oxidase) as a product of P-450IIIA gene subfamily. Drug Metabolism and Disposition, 17, 197-207.
6. CREAVEN, P. J., PARKE, D. V. and WILLIAMS, R. T., 1965, A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes. Biochemical Journal, 96, 390-398.
7. DAUJAT, M., FABRE, I., DIAZ, D., PICHARD, L., FABRE, G,. FABRE, J. M., SAINT-AUBERT, B. and MAUREL, P., 1990, Inducibility and expression of class IA and IIIA cytochromes P450 in primary cultures of adult human hepatocytes. Biochemical Pharmacology (Life Sciences Advances), 9, 315-326.
8. DAUJAT, M., PICHARD, L., DALET, C., LARROQUE, C., BONFILS, C., POMPON, D., LI, D., GUZELIAN, P. S. and MAUREL, P., 1987, Expression of five forms of microsomal cytochrome P-450 in primary cultures of rabbit hepatocytes treated with various classes of inducers. Biochemical Pharmacology, 36, 3597-3607.
9. DAUJAT, M., PICHARD, L., FABRE, I., PINEAU, T., FABRE, G., BONFILS, C. and MAUREL, P., 1991, Induction protocols for cytochrome P450IIIA in vivo and in primary cultures of animal and human hepatocytes. Methods in Enzymology, 206, 345-353.
10. DIAZ, D., FABRE, I., DAUJAT, M., SAINT AUBERT, P., BORIES, P., MICHEL, H. and MAUREL, P., 1990, Omeprazole is an aryl hydrocarbon-like inducer of human cytochrome P450. Gastroenterology, 99, 737-747.
11. DONATO, M. T., CASTELL, J. V. and GOMEZ-LECHON, M. J., 1995, Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metabolism and Disposition, 23, 553-558.
12. EKINS, S., WILLIAMS, J. A., MURRAY, G. I., BURKE, M. D., MARCHANT, N. C., ENGESET, J. and HAWKSWORTH, G. M., 1996, Xenobiotic metabolism in rat, dog and human precision-cut liver slices, freshly isolated hepatocytes and vitrified precision-cut liver slices. Drug Metabolism and Disposition, 24, 990-995.
13. FABRE, G., BOURRIÉ, M., MARTI, E., FABRE, I., ROQUE, C., SAINT-AUBERT, B., JOYEUX, H., MAUREL, P., BERGER, Y. and CANO, J. P., 1990, Inducibility of both cytochrome P-450 and UDP-glucuronosyl transferase isozymes in primary cultures of human hepatocytes. Biochemical Pharmacology (Life Sciences Advances), 9, 79-91.
14. FABRE, G., CREVAT-PIZANO, P., DRAGNA, S., COVO, J., BARRA, Y. and CANO, J. P., 1988b, Involvement of the macrolide antibiotic cytochrome P450-LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochemical Pharmacology, 37, 1947-1953.
15. FABRE, G., RAHMANI, R., PLACIDI, M., COMBALBERT, J., COVO, J., CANO, J. P., COULANGE, C., DUCROS, M. and RAMPAL, M., 1988a, Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochemical Pharmacology, 37, 4389-4397.
16. GED, C., ROUILLON, J. M., PICHARD, L., COMBALBERT, J., BRESSOT, N., BORIES, P., MICHEL, H., BEAUNE, P. and MAUREL, P., 1989, The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. British Journal of Clinical Pharmacology, 28, 373-387.
17. GOMEZ-LECHON, M. J., LOPEZ, P., DONATO, T., MONTOYA, A., LARRAURI, P., GIMENEZ, P., TRULLENQUE, R., FABRA, R. and CASTELL, J. V., 1990, Culture of human hepatocytes from small surgical liver biopsies: biochemical characterization and comparison with in vivo. In Vitro Cell Development in Biology, 26, 67-74.
18. GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T. and WAXMAN, D. J., 1986, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype of genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 5051-5060.
19. GUILLOUZO, A., 1997, Biotransformation of drugs by hepatocytes. In In Vitro Methods in Pharmaceutical Research (Orlando: Academic Press), pp. 411-429.
20. ISOM, H. C. and GEORGOFF, I., 1984, Quantitative assay for albumin-producing liver cells after simian virus 40 transformation of rat hepatocytes maintained in a chemically-defined medium. Proceedings of the National Academy of Sciences, USA, 81, 6378-6382.
21. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147-171.
22. KOCAREK, T. A., SCHUETZ, E. G., STROM, S. C., FISHER, R. A. and GUZELIAN, P. S., 1995, Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metabolism and Disposition, 23, 415-421.
23. LI, A. P., 1997, Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug drug interactions. In Advances in Pharmacology, vol. 43 (Orlando: Academic Press), pp. 103-130.
24. LI, A. P., RASMUSSEN, A., XU, L. and KAMINSKI, D. L., 1995, Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 274, 673-677.
25. MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JOYEUX, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal, 6, 752-758.
26. MCKINNON, R. A., HALL, P. M., QUATTROCHI, L., TUKEY, R. H. and MCMANUS, M. E., 1991, Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology, 14, 848-852.
27. MINERS, M. O. VERONESE, M. E. and BIRKETT, D. J., 1994, In vitro approaches for the prediction of human drug metabolism. In J. A. Bristol (ed.), Annual Reports in Medicinal Chemistry, vol. 29 (Orlando: Academic Press), pp. 306-316.
28. NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREIZEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K. and NEBERT, D. W., 1993, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biology, 12, 1-51.
29. OLINGA, P., MEREMA, M., HOF, I. H., DE JONG, K. P., SLOOFF, M. J. H., MEIJER, D. K. F. and GROOTHUIS, G. M. M., 1998, Effect of human liver source on the functionality of isolated hepatocytes and liver slices. Drug Metabolism and Disposition, 26, 5-11.
30. PELKONEN, O., SOTANIEMI, E. A. and AHOKAS, J. T., 1985, Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and inter-species comparison. British Journal of Clinical Pharmacology, 19, 59-66.
31. PICHARD, P., FABRE, I., FABRE, G., DOMERGUE, J., SAINT AUBERT, B., MOURAD, G. and MAUREL P., 1990, Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes. Drug Metabolism and Disposition, 18, 595-606.
32. POLLARD, H. B., MENARD, R., BRANDT, H. A., PAZOLES, C. J., CREUTZ, C. E. and RAMU, A., 1978, Application of Bradford's protein assay to adrenal gland subcellular fractions. Analytical Biochemistry, 86, 761-763.
33. RODRIGUES, A. D., 1994, Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochemical Pharmacology, 48, 2147-2156.
34. SESARDIC, D., BOOBIS, A. R., EDWARDS, R. J. and DAVIES, D. S., 1988, A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology, 26, 363-372.
35. SILVA, J. M., MORIN, P. E., DAY, S. H., KENNEDY, P. P., RUSHMORE, T., YERGEY, J. A. and NICOLL-GRIFFITH, D. A., 1998, Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metabolism and Disposition, 26, 490-496.
36. SHIMADA, T., YAMAZAKI, H., MINURA, M., INUI, Y. and GUENGERICH F. P., 1994, Inter-individual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals; studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
37. TUCKER, G. T., 1992, The rational selection of drug interaction studies; Implications of recent advances in drug metabolism. International Journal of Clinical Pharmacology, Therapeutics and Toxicology, 30, 550-553.
38. WADHWA, N. K., SCHROEDER, T. J., PESCE, A. J., MYRE, S. A., CLARDY, C. W. and FIRST, M. R., 1987, Cyclosporin drug interactions: a review. Therapeutics and Drug Monitoring, 9, 399-406.
39. WATKINS, P. B., MURRAY, S. A., WINKELMAN, L. G., HEUMAN, D. M., WRIGHTON, S. A. and GUZELIAN, P. S., 1989, Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Journal of Clinical Investigation, 83, 688-697.
40. WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ-PICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences, USA, 82, 6310-6314.
41. WRIGHTON, S. A. and STEVENS, J. C., 1992, The human hepatic cytochromes P450 involved in drug metabolism. Critical Review in Toxicology, 22, 1-21.